Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

AE_FY2014_FY2013

Alzheimer Europe (AE) defines its mission as "changing perceptions, practice and policy in order to improve the access of people with dementia and their carers to treatment options and care services". In addition, the organisation has defined its guiding philosophy as "promoting the autonomy and self-determination of people with dementia and their...

Funding Programme
Start Date
End Date
Total Funding
€ 285 168
European Countries Involved

affecTive basEd iNtegrateD carE for betteR Quality of Life

TeNDER

With an increasingly growing population in Europe, cognitive impairments as well as heart diseases are a major social and health issue. 1.2 million people in Europe are affected by Parkinson's disease (PD) while Alzheimer’s disease remains one of the biggest global public health challenges our generation is facing, while Cardiovascular disease...

Funding Programme
Start Date
End Date
Total Funding
€ 5 698 333
European Countries Involved

Age-dependent mechanisms of sporadic Alzheimer’s Disease in patient-derived neurons

AGEMEC

Sporadic Alzheimer’s Disease (AD) accounts for the overwhelming majority of all AD cases and exclusively affects people at old age. However, mechanistic links between aging and AD pathology remain elusive. We recently discovered that in contrast to iPSC models, direct conversion of human fibroblasts into induced neurons (iNs) preserves signatures...

Funding Programme
Start Date
End Date
Total Funding
€ 1 499 565
European Countries Involved

Age-modified forms of Amyloid-β as initiator of Alzheimer Disease pathogenesis and mediator of Aβ-tau interaction: a study in a Drosophila model and Aβ immunized human Alzheimer patients

ALZPROTAGEING

Alzheimer Disease (AD) is the commonest form of dementia, with ageing as the main risk factor. There are currently over 6 million people with dementia in the European Union (EU). The increasingly ageing population makes AD an economic and social burden for our society, thus investigating the pathological mechanisms of AD and the characterization of...

Funding Programme
Start Date
End Date
Total Funding
€ 221 606
European Countries Involved

Alterations in Memory Networks in Mild Cognitive Impairment and Alzheimer’s disease: Relating the Impact of Amyloid Burden with PIB-PET on Neuronal Activation as Assessed with fMRI

MCI_AD PIB-PET_FMRI

The main objective of this first 2-year period as a post-doctoral research fellow at BWH/MGH Harvard Medical School is to get training in novel Magnetic Resonance Imaging (MRI) and Pittsburgh Compound B–Positron Emission Tomography (PIB-PET) techniques, their analysis methods, and applications to aging and age-related neurodegenerative diseases...

Funding Programme
Start Date
End Date
Total Funding
€ 221 370
European Countries Involved

Altered mRNA translation as a pathogenic mechanism across neurodegenerative diseases

TRANSNEURO

Neurodegenerative and neurodevelopmental diseases constitute a major health burden, and in spite of several decades of intensive research, the molecular mechanisms underlying these diseases are still poorly understood, and effective drug treatments are generally lacking. Alterations in protein synthesis have been implicated in several of these...

Funding Programme
Start Date
End Date
Total Funding
€ 1 830 000
European Countries Involved

ALzheimer COoperative Valuation in Europe

The JA will be contribute to public health programmes in Europe and develop Alzheimers disease (AD) and dementia prevention and care models in different European countries. The aim is to contribute to improvements in health by supporting and facilitating quality and efficiency of public health and healthcare policies and interventions. Synergy and...

Funding Programme
Start Date
End Date
Total Funding
€ 613 100

Alzheimer Disease - gut connection

AD-gut

Alzheimer’s disease (AD) is the leading cause of dementia in the Western world and to date no cure nor any preventive strategy are available for this neurodegenerative disorder. Bacterial 16S rRNA sequencing from fecal samples revealed a remarkable shift in the gut microbiota of conventionally-raised AD mice compared to healthy, wild-type mice...

Funding Programme
Start Date
End Date
Total Funding
€ 7 686 620
European Countries Involved

Alzheimer disease progression: Molecular studies of Abeta amyloid peptides aggregation and trafficking in neuronal cells

ADPROGRES

Amyloid fibrils are likely causative or contributing agents in diseases such as Alzheimer’s disease, type 2 diabetes, Parkinson’s disease, and transmissible spongiform encephalopathies. AD represents a major health problem and heavy economic burden in industrialized countries. AD is characterized in pathology by the presence of several kinds of...

Funding Programme
Start Date
End Date
Total Funding
€ 75 000
European Countries Involved

Alzheimer Europe (2015-2017)

The 2015-2017 framework programme of Alzheimer Europe aims to achieve the following objectives:

1. Increasing knowledge about current national dementia policies and strategies, in order to promote best practices and reduce inequalities in dementia care in Europe (dementia-friendly communities, legal capacity and proxy decision making, care...

Funding Programme
Start Date
End Date
Total Funding
€ 422 880
European Countries Involved

Alzheimer Europe (2015-2017)

The 2015-2017 framework programme of Alzheimer Europe aims to achieve the following objectives: Increasing knowledge about current national dementia policies and strategies, in order to promote best practices and reduce inequalities in dementia care in Europe (dementia-friendly communities, legal capacity and proxy decision making, care standards...

Funding Programme
Start Date
End Date
Total Funding
€ 422 880
European Countries Involved

Alzheimer Europe - AE FY 2011

Alzheimer Europe defines its mission as "changing perceptions, practice and policy in order to improve the access of people with dementia and their carers to treatment options and care services". To achieve its mission, Alzheimer Europe has defined the following six objectives in its strategic plan which covers the period of 2006-2010:Representing...

Funding Programme
Start Date
End Date
Total Funding
€ 200 000
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).